I should have named this edition 🥩 Boeuf Bourguignon & Château Margaux 🍷 as I am late and I apologize.
You should have got this edition earlier but I fixed the back garden fence and it took me much more time than I expected.
Here’s my edition of the week, sans plus tarder.
Corporate France Exports Itself While the State Flounders
As Sanofi's $2.2 billion acquisition of Dynavax and Safran's €200 million India expansion reveal the sophistication of corporate strategy, France's government has been forced to extend its emergency budget measures into 2026. This week exposed a structural paradox: French industrial champions are deploying capital with long-term discipline, yet the state cannot organize itself to manage deficit targets or provide budgetary continuity. The manufacturing PMI rebound, driven entirely by export strength and foreign demand, suggests that France's economic future lies not in domestic growth, but in the disciplined retreat of its firms toward markets where execution matters more than politics.
France’s private sector closed this week in studied motion, neither panicked nor jubilant, while the government performed the administrative ballet it has now perfected: the emergency special law. The two phenomena are not unrelated; they reveal the deepening fissure between the rationality of corporate France and the paralysis of state France.
Late Nights at the National Assembly
On Tuesday evening, the National Assembly passed emergency legislation to permit the government to continue operations on the 2025 budget framework into January 2026, having failed yet again to finalize a comprehensive budget by year-end. This is the second such measure in two years.
The cost of the previous special law, deployed in 2025 to keep the state functioning, was estimated at €12 billion in efficiency losses. The current measure, by government admission, is temporary scaffolding; the structural problem of deficit management remains unsolved. France’s deficit is projected at 5.4 percent of gross domestic product for 2025, the highest among eurozone nations, and the government has pledged to bring it below 5 percent in 2026. The means by which this will be achieved, however, remains obscured by parliamentary gridlock. No single political faction controls a majority; the Prime Minister negotiates daily for the survival of his government.
The calendar advances; the budget does not.
Simultaneously, on December 24, Sanofi announced the acquisition of Dynavax Technologies for $2.2 billion in cash — the pharmaceutical company’s fifth major acquisition in 2025. The transaction was announced immediately after the U.S. Food and Drug Administration declined to approve Sanofi’s tolebrutinib candidate for multiple sclerosis, a late-stage pipeline setback of significance. The response was neither panic nor withdrawal, but disciplined capital deployment toward a different objective. Dynavax brings a marketed adult hepatitis B vaccine and a differentiated shingles vaccine candidate into Sanofi’s immunization portfolio. The acquisition will close in the first quarter of 2026, and Sanofi’s financial guidance for 2025 is not affected. This is the language of institutional execution: objective, sequential, indifferent to temporal pressures that might disorder a less disciplined organization.
The same pattern appears at Safran. In late November, the French aerospace group announced that its annual revenue from India, currently in the single hundreds of millions, will triple to exceed €3.4 billion by 2030.
Half of this revenue will derive from manufacturing operations established within India. The company is opening what it describes as the world’s largest maintenance and repair facility for LEAP engines in Hyderabad, an investment of €200 million, with operations commencing in 2026. India’s aviation market is the fastest-growing globally; Indian airlines have ordered over 1,500 new aircraft.
This expansion is not opportunistic or speculative; it is calculated response to structural demand in a market where France’s industrial competencies command premium value. Safran is not expanding in France; it is relocating capacity and capability to where the customer growth resides.
The implications of this corporate behavior become visible in the manufacturing data released last week. France’s manufacturing PMI rose to 50.6 in December, up sharply from 47.8 in November, the highest level in more than three years. The improvement broke four months of contraction. Yet it was driven, unambiguously, by foreign demand and export recovery, not domestic demand.
The composite PMI, which captures both manufacturing and services, fell to 50.1, indicating near-stagnation at the broader economy level. Services PMI declined to 50.2 from 51.4, reflecting continued hesitation among clients due to budget uncertainty. Manufacturing stabilized because external demand is robust and because companies such as Safran are executing overseas growth plans with precision. The domestic economy remains fragile.
This divergence merits structural interpretation. French industrial champions, Sanofi, Safran, LVMH, Airbus, are not waiting for the state to organize fiscal policy or provide investment certainty. They are deploying capital toward markets where their capabilities command value: therapeutics through acquisition, aerospace maintenance in India, luxury goods in global markets where wealth concentrates. These are decisions made with patient capital and long operational horizons. They do not depend on government clarity because they operate in domains where execution and market position supersede political cycles.
Conversely, the government cycles through emergency measures because the parliament cannot aggregate sufficient consensus for structural fiscal decisions. The deficit remains elevated; employment pressures are gathering; household confidence continues to track below historical average. These are not temporary conditions. They are the structural consequences of a parliament without majority and a society whose political factions cannot reconcile on public spending priorities.
France’s economic future, therefore, will be authored not in the National Assembly, but in the board rooms and capital allocation decisions of its multinational corporations… They are becoming less dependent on domestic stability and more focused on external markets.
This is rational adaptation; it is also, fundamentally, a retreat. The state will manage its budget through means it has not yet solved. Corporate France will continue executing with discipline in environments where politics intrudes far less. The two will proceed in parallel, increasingly disconnected.